NEW! Subscribe to Medtech Pro and get one or all of our reports, plus much more.

Cardiovascular Devices - Growth Opportunities in Emerging Markets

68 Pages | 67 Exhibits | Forecasts Through 2017
market-report-samples/GlobalMarketSegments2.jpg market-report-samples/GlobalMarketSegments3caps.jpg market-report-samples/GlobalMarketSegmentsCaps.jpg
Buy Now

Overview

A timely and unique growth opportunity exists for cardiovascular device manufacturers seeking to offset some of the tepid or declining growth they have been experiencing in the US and Western European markets. As a result, multinational cardiovascular device companies have been increasing their investments in emerging nations - and they are reaping the rewards, with demand for some cardiovascular devices increasing at solid double-digit rates in many emerging countries, including the BRIC nations (Brazil, Russia, India, and China) and Turkey.

Combined, these five emerging countries performed an estimated 2.2 million cardiovascular procedures in 2013 - including interventional cardiology procedures, cardiothoracic surgeries (eg, CABG surgery, heart valve procedures, congenital heart disease procedures, and procedures for aortic aneurysms), and cardiac rhythm management procedures (eg, pacemaker/defibrillator implantations and cardiac ablations) - and that number is projected to increase to more than 3.5 million by 2017, a compound annual growth rate of about 13%. China alone is responsible for nearly 60% of that total (about 1.3 million procedures in 2013) and also offers the highest growth rate of the five over the forecast period (16.8%).

Interventional cardiology procedures, heart rhythm procedures, and heart valve procedures (particularly minimally invasive valve procedures) are expected to exhibit the highest procedural growth over the next several years in these five nations, with solid double-digit growth rates anticipated for all of these procedure categories through 2017. These same categories also represent four of the top five cardiovascular markets by procedure volume, with percutaneous coronary intervention, accounting for more than 60% of that total.

Demand for cardiovascular devices in the BRIC nations and Turkey is expected to remain high over the next five years, driven by aging populations, expanding rates of diabetes and heart disease, an ongoing trend toward urbanization, and continued government investments in healthcare infrastructure. At the same time, these countries present some important challenges to foreign companies seeking to do business there, including weak patent laws, the potential for corruption, and disparities in access to healthcare.

This dynamic, new report from Life Science Intelligence offers a detailed look at the most promising future growth opportunities for cardiovascular device companies in the BRIC nations and Turkey. Included are analyses and comparisons of cardiovascular procedure volumes, growth rates, and market drivers/limiters for each country covered. The report also provides an overview of multinational cardiovascular device company strategies for penetrating these markets as well as an assessment of next-generation technologies, including "leadless" pacemakers and defibrillators and bioresorbable coronary stents, and their potential to further expand growth in emerging market regions.

Table of Contents

MARKET OVERVIEW
Growth Drivers and Limiters
Population and Disease Trends
The Diabetes Pandemic
Rising Prevalence of Ischemic Heart Disease
Top Cardiovascular Device Opportunities

CORONARY REVASCULARIZATION
PCI: Emerging Markets offer A Rare Growth Opportunity
Strong Demand For Drug-Eluting Stents
Radial PCI On The Rise
CABG Surgery

CARDIAC RHYTHM MANAGEMENT PROCEDURES
CRT Poised For Solid Gains
Cardiac Ablation: Reaching Critical Mass

HEART VALVE PROCEDURES

CARDIOVASCULAR DEVICE OPPORTUNITIES IN EMERGING MARKETS, BY COUNTRY

CHINA
China's Healthcare Market: Opportunities and Challenges
Top Five Cardiovascular Growth Opportunities in China
PCI Procedures in China
CRM Procedures in China
Heart Valve Procedures in China
Other High-Growth/High-Volume Procedures in China
Multinational Cardiovascular Device Players See China As "Key" To Emerging Market Strategy

INDIA
Top Five Cardiovascular Growth Opportunities in India
Cardiac Rhythm Management Procedures: Growth Leader in India
PCI Procedures in India
CABG and Heart Valve Procedures in India
Congenital Heart Disease Procedures in India

BRAZIL
Top Five Cardiovascular Growth Opportunities in Brazil
Heart Valve Procedures in Brazil: Growth in MIS
Aortic Aneurysm Repair in Brazil
Brazil's Loss Leaders

RUSSIA
Top Five Cardiovascular Growth Opportunities in Russia
interventional Cardiology Procedures in Russia
Heart Rhythm Procedures in Russia
Other Growth Procedures in Russia

TURKEY
Top Growth Procedures in Turkey
PCI Procedures in Turkey
Turkey Attracts Multinationals

MULTINATIONALS LOOK TO EMERGING MARKETS FOR GROWTH
Medtronic: A Case Study in Emerging Market Strategy

IMPACT OF NEW TECHNOLOGIES IN EMERGING MARKETS
Boston Scientific
St. Jude Medical
Abbott Vascular

LIST OF EXHIBITS
Exhibit 1: Global Cardiovascular Therapeutic Device Market, 2014
Exhibit 2: Cardiovascular Procedures in the BRIC Nations and Turkey
Exhibit 3: Cardiovascular Procedure Growth, BRIC Nations and Turkey
Exhibit 4: Population Rankings for the BRIC Nations and Turkey, 2014
Exhibit 5: Growth in Per Capita Government Expenditures on Health
Exhibit 6: Growth in Age 65 and Over Populations, Emerging Countries, 2012-2017E
Exhibit 7: Top 10 Countries/Territories For Number of People with Diabetes (Age 20-79 years), 2013 and 2035
Exhibit 8: Population with Ischemic Heart Disease (000s), 2012-2017E
Exhibit 9: Population with Ischemic Heart Disease (000s), 2017, by Country
Exhibit 10: Emerging Markets: Top 10 Procedure Volume Growth Opportunities for Cardiovascular Devices, 2012-2017E
Exhibit 11: Emerging Markets: Top Five Cardiovascular Markets by Case Volume, 2014E
Exhibit 12: Emerging Market Contribution to Worldwide PCI Device Revenues, 2013-2017E
Exhibit 13: Percutaneous Coronary intervention, Emerging Markets Procedure Forecast Versus US and Germany, 2012-2017E
Exhibit 14: Stent Implantations (units), Emerging Markets Forecast, 2012-2017E
Exhibit 15: DES Implantations (units), Emerging Markets Forecast, 2012-2017E
Exhibit 16: Growth in Radial Access For PCI: Emerging Nations vs. US and Germany
Exhibit 17: CABG Surgery, Emerging Markets Procedure Forecast Versus US and Germany, 2012-2017E
Exhibit 18: Global CRM Device Market; Share by Supplier, 2014
Exhibit 19: CRM Procedures, Emerging Markets Procedure Forecast, 2012-2017E
Exhibit 20: CRT/CRT-D Implantations, Emerging Markets Procedure Forecast, 2012-2017E
Exhibit 21: CRT-P and CRT-D Procedural Growth Projections in the BRIC Nations and Turkey, 2012-2017
Exhibit 22: Conventional Pacemaker Implantations, Emerging Markets Procedure Forecast, 2012-2017E
Exhibit 23: ICD Implantations, Emerging Markets Procedure Forecast, 2012-2017E
Exhibit 24: Global AF Device Market; Share by Supplier, 2014
Exhibit 25: Worldwide Electrophysiology Device Market, Revenue Forecast, 2012-2017E
Exhibit 26: Cardiac Ablation, Emerging Markets Procedure Forecast, 2012-2017E
Exhibit 27: TAVR Global Market Forecast, 2013-2019E
Exhibit 28: Heart Valve Procedures,Emerging Markets Procedure Forecast, 2012-2017E
Exhibit 29: Minimally invasive Valve Procedures, Emerging Markets Procedure Forecast, 2012-2017E
Exhibit 30: Growth in China's Middle Class; Percent of Urban Chinese Households With Middle Class incomes, 2000-2022
Exhibit 31: Ischemic Heart Disease in China, 2012-2017E
Exhibit 32: Leading Causes of Death in China
Exhibit 33: China: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
Exhibit 34: China: Top Five Cardiovascular Procedures by Volume, 2014
Exhibit 35: Percutaneous Coronary intervention in China, 2012-2017E
Exhibit 36: CRM Procedures in China, 2012-2017E
Exhibit 37: CRM Procedures in China, by Product Type, 2014
Exhibit 38: Heart Valve Procedures in China, 2012-2017E
Exhibit 39: Congenital Heart Disease Procedures in China, 2012-2017E
Exhibit 40: CABG Surgery, Cardiac Ablation, and Aortic Aneurysm Procedure Volumes in China, 2012-2017E
Exhibit 41: India: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
Exhibit 42: India: Top Five Cardiovascular Procedures by Case Volume, 2014
Exhibit 43: Ischemic Heart Disease Prevalence in India, 2012-2017E
Exhibit 44: CRM Procedures in India, 2012-2017E
Exhibit 45: Cardiac Ablation in India, Procedure Forecast, 2012-2017E
Exhibit 46: Percutaneous Coronary intervention in India, 2012-2017E
Exhibit 47: CABG and Heart Valve Procedures in India, 2012-2017E
Exhibit 48: Congenital Heart Disease Procedures in India, 2012-2017E
Exhibit 49: Brazil: Top Five Cardiovascular Procedures by Case Volume, 2014
Exhibit 50: Brazil: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
Exhibit 51: Top Ten Causes of Death in Brazil, 2010
Exhibit 52: Trends in Coronary Stenting in Brazil
Exhibit 53: CRM Procedures in Brazil, 2012-2017E
Exhibit 54: Heart Valve Procedures in Brazil, 2012-2017
Exhibit 55: Aortic Aneurysm Repair Procedures in Brazil, 2012-2017E
Exhibit 56: Physicians Per 1,000 Population; BRIC Nations vs. Selected Others
Exhibit 57: Russia: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
Exhibit 58: Russia: Top Five Cardiovascular Procedures by Case Volume, 2014
Exhibit 59: Trends in Coronary intervention in Russia, 2012-2017E
Exhibit 60: Pacemaker Implants and CABG Surgery in Russia, 2012-2017E
Exhibit 61: Trends in Heart Valve Procedures in Russia, 2012-2017E
Exhibit 62: Aortic Aneurysm Repair Procedures in Russia, 2012-2017E
Exhibit 63: Turkey: Top Five Fastest Growing Cardiovascular Procedures, 2012-2017
Exhibit 64: Turkey: Top Five Cardiovascular Procedures by Case Volume, 2014
Exhibit 65: Percutaneous Coronary intervention in Turkey, 2012-2017E
Exhibit 66: Moderate Volume/Growth Opportunities in Turkey
Exhibit 67: Medtronic's Emerging Market Revenue Mix, FY2013

Companies Covered

Abbott Laboratories
Abbott Vascular
Apollo Hospitals Enterprise Ltd.
Biosense Webster/Johnson & Johnson
Biostar
Boston Scientific
China Kanghui Holdings
Covidien
Edwards Lifesciences
GE Healthcare
LifeTech Scientific Corp.
Medicall Biomedikal AS
Medtronic
Philips Medical
St. Jude Medical
Stryker
Terumo